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Background: A fusion gene between the echinoderm microtubule-associated protein-like 4 
(EML4) and the anaplastic lymphoma kinase (ALK) has recently been identified in non-small 
cell lung cancers (NSCLCs). We screened for EML4-ALK fusion genes and examined the 
clinicopathological and genetic characteristics of the fusion-harboring NSCLC tumors. 
Methods: We examined 313 NSCLC samples from patients who underwent resection at our 
Hospital between May 2001 and July 2005. We screened for the fusion genes using the 
reverse transcription polymerase chain reaction (RT-PCR) assay and confirmed the results 
with direct sequencing. We also examined mutations in the epidermal growth factor receptor 
(EGFR), KRAS, and ERBB2 genes. 
Results: Five EML4-ALK fusion genes were detected (four from 111 female samples and 
one from 202 male samples; 1.6% overall). All five genes were found in adenocarcinomas 
and accounted for 2.4% of the 211 adenocarcinoma samples. One EML4-ALK fusion was 
variant 1, and two were variant 3. In addition, we also found two new fusion variants. 
Patients with fusion-positive tumors were non-smokers or light smokers. Among the 211 
adenocarcinomas, mutations in EGFR, KRAS, and ERBB2 were detected in 105, 29, and 7 
tumors, respectively. Interestingly, all of the fusion-positive NSCLCs had no mutations within 
these genes.  
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Conclusions: The EML4-ALK fusion genes were observed predominantly in 
adenocarcinomas, in female or non-smoking populations. Additionally, the EML4-ALK 




Primary lung cancer is the leading cause of cancer-related death in many industrialized 
countries. Although a combination of surgery, chemotherapy, and/or radiotherapy can be 
used to treat this disease, the prognosis for patients remains dismal. In an effort to develop 
new treatment strategies, several molecular-targeting drugs have recently been developed. 
It is known that epidermal growth factor receptor (EGFR) gene mutations are one of the 
causes of primary lung adenocarcinomas, and to some extent, tyrosine kinase inhibitors that 
target EGFR (e.g., gefitinib and erlotinib) have proven successful for controlling this 
disease.1-11 Therefore, the identification of the key oncogenes for lung cancer is a very 
important step toward the development of novel molecular-targeting agents. Interestingly, 
EGFR gene mutations have been revealed to be exclusive in adenocarcinomas, and most of 
these patients are from the Asian, female, non-smoker population.6-9, 11-22, 24 Gefitinib is most 
commonly applied to lung adenocarcinomas with these typical clinicopathological features. 
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These facts underscore the importance of discovering favorable clinicopathologic and 
genetic characteristics for each type of tyrosine kinase inhibitor therapy.  
Recently, Soda and colleagues (2007) identified another type of tyrosine kinase with 
accelerated activity in a fusion gene between the echinoderm microtubule-associated 
protein-like 4 (EML4) and the anaplastic lymphoma kinase (ALK).23 Indeed, ALK kinase 
inhibitors have already been developed and have been reported to suppress the growth of 
EML4-ALK fusion positive cells.23, 24, 26, 27 Thus, treatment with ALK inhibitors can be 
effective for non-small cell lung cancer (NSCLC) patients whose tumors contain an 
EML4-ALK fusion.  
In this report, we examine the EML4-ALK fusion gene in a relatively large number of clinical 
samples, and investigate its clinicopathologic and genetic background, in order to identify 
useful information on patient selection for ALK inhibitor therapy.   
 
 
[Materials and Methods] 
Patients and sample collection 
This study included 313 Japanese NSCLC patients (211 adenocarcinomas, 75 squamous 
cell carcinomas, 17 large cell carcinomas, and 10 other NSCLCs) who underwent 
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pulmonary resection at Kyoto University Hospital between May 2001 and July 2005. The 
pathological stage was evaluated according to the current international TNM staging system 
and the classification of the World Health Organization (WHO). Patient data were obtained 
from inpatient and outpatient medical records. All patients were followed-up (either to the 
time of death or through April 2009) using outpatient medical records and by letter or phone. 
The genetic analyses in the present study were approved by the Ethics Committee of our 
institute.  
Preparation of cDNA 
All of the tumor tissues were stored in RNAlater TissueProtect Tubes (Qiagen) immediately 
after pulmonary resections for RNA stabilization. Total RNA was extracted from specimens 
using the RNeasy Mini Kit (Qiagen), and the RNA extract was incubated with RNase-free 
DNase I (Qiagen) to remove contaminating DNA. Reverse-transcription of total RNA was 
performed using Ready-To-Go You-Prime First-Strand Beads (Amersham Bioscience) to 
generate cDNA.  
Detection of EML4-ALK fusion genes 
For detection of EML4-ALK fusion cDNAs, we performed reverse transcription polymerase 
chain reaction (RT-PCR) assays using the primer set described by Soda et al.:23, 27 
5’-GTGCAGTGTTTAGCATTCTTGGGG-3’ (forward primer, on exon 13 of EML4) and 
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5’-TCTTGCCAGCAAAGCAGTAGTTGG-3’ (reverse primer, on exon 21 of ALK). We also 
used the following primer set to detect other types of fusion transcripts consisting of the 
upper exons of EML4 and ALK: 5’-GTCAGCTCTTGAGTCACGAGTT-3’ (forward primer, on 
exon 2 of EML4) and 5’-TCTTGCCAGCAAAGCAGTAGTTGG-3’ (reverse primer, on exon 
21 of ALK). Amplification was initiated by pre-incubation for 15 min at 95°C for the initial 
activation, followed by 35 cycles of: denaturation for 30 s at 95°C, primer annealing for 30 s 
at 66°C, and elongation for 1 min at 72°C using HotStar Taq Master Mix Kit (Qiagen). A 12µL 
aliquot of each reaction mixture was electrophoresed through a 2% agarose gel and stained 
by ethidium bromide for visualization under ultraviolet light. We used the primers 
5’-ACAACAGCCTCAAGATCATCAG-3’ (forward) and 5’-TCTTCTGGGTGGCAGTGATG-3’ 
(reverse) to amplify the GAPDH gene as an internal control. GAPDH amplification was 
performed by pre-incubation for 10 min at 95°C for initial activation, followed by 35 cycles of: 
denaturation for 15 s at 94°C, primer annealing for 15 s at 59°C, and elongation for 15 s at 
72°C.  
Detection of the mutations within the EGFR, KRAS, and ERBB2 genes 
As reported previously, we analyzed mutations in the EGFR (exons 18-21)28 and ERBB2 
(exons 19-20) genes 30 by the PCR-single strand conformational polymorphism 
(PCR-SSCP) technique. We also used a modified mutagenic restriction fragment length 
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polymorphism (PCR-RFLP) method to screen for mutations in codon 12 of the KRAS 
gene.28  
Histopathological analysis 
All of the surgical specimens were subjected to hematoxylin-eosin staining at the 
Department of Diagnostic Pathology of our hospital. Two board-certified pathologists 
independently reviewed the slides and performed diagnoses according to the 2004 WHO 




Detection of the EML4-ALK fusion gene and analysis of fusion patterns 
Using RT-PCR, five fusion transcripts were detected (Fig. 1). The control GAPDH gene was 
amplified in all of the 313 samples (data not shown). The EML4 (exon 2)-ALK primer set 
amplified EML4-ALK fusion genes from all five of these patients (1-5), and the EML4 (exon 
13)-ALK primer set amplified fusion genes from patients 1, 4, and 5. Direct sequence 
analysis confirmed the variant that was harbored by each tumor (Table 1). As a control, no 
gene was amplified by both primer sets from A549 cells, which do not carry the EML4-ALK 
fusion gene. Tumors from patient 4 carried a new fusion variant, which involved the fusion of 
full length exon 20 of EML4 and full length exon 20 of ALK with an 18-bp insertion sequence 
(5’-CTGACCACCCACCTGCAG-3’) between the two exons. This inserted sequence is 
identical to the last 18-bp of ALK intron 19, which means that the break point of ALK was 
located at an upstream intron (Fig. 2A, B).   
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The tumor from patient 5 also had a novel transcript that involved a fusion between 
full-length EML4 exon 17 and full-length ALK exon 20, with a 68-bp insertion sequence 
(5’-AGTCTTGCTCTGTCTCCCAGGCTGGAGTGCAGTGGCAATTTACACATTTCAATTCAT
TCGATCCTCAG-3’) (Fig. 2A, C). Six sequences identical to the first part of the 14-bp 
sequence (5’-AGTCTTGCTCTGTC-3’) were found in ALK introns: one sequence in intron 1, 
three in intron 3, one in intron 4, and one in intron 8. The reversed sequence 
(5’-GACAGAGCAAGACT-3’) was also found in ALK introns: one each in introns 1, 3, 4, 5, 
and 26. Thus 11 copies of this 14-bp sequence were scattered throughout the ALK introns. 
One identical sequence to the middle part of the inserted sequence 
(5’-TCCCAGGCTGGAGTGCAGT-3’, 19-bp) was also found in ALK intron 4, and its 
reversed sequence (5’-ACTGCACTCCAGCCTGGGA-3’) was found in ALK intron 5. 
Interestingly, we found nineteen sequences resembling this middle inserted sequence in 
ALK introns, but they lacked the first thymidine and the last three nucleotides (i.e., 
5’-CCCAGGCTGGAGTGC-3’). We also found twenty-one reversed copies of this sequence 
in ALK introns, thus ALK introns had 42 copies of 5’-CCCAGGCTGGAGTGC-3’ and its 
reversed sequence. Among them, thirteen copies of 5’-CCCAGGCTGGAGTGCAGT-3’ and 
ten of the reversed sequence 5’-ACTGCACTCCAGCCTGGG-3’ were found. In ALK intron 
19, one identical sequence to the last part of the inserted sequence 
(5’-GGCAATTTACACATTTCAATTCATTCGATCCTCAG-3’, 35-bp) was also observed, and 
its reversed sequence (5’-CTGAGGATCGAATGAATTGAAATGTGTAAATTGCC-3’) was 
found in ALK intron 19. Thus, the inserted sequence of patient 5 consists of three ALK intron 
sequences. The EML4-ALK fusions from patients 4 and 5 resemble variant 3b, in which 
exon 6 of EML is fused to exon 20 of ALK with a 33-bp insertion.  
Patients with EML4-ALK fusion-positive NSCLCs 
Out of 313 patients, 5 (1.6%) had tumors that contained EML4-ALK fusion genes. These five 
fusion-positive tumors were adenocarcinomas, and the clinicopathologic profiles of the five 
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fusion-positive vs. negative adenocarcinoma patients are shown in Table 2. No patients with 
EML4-ALK fusion-positive tumors had received any induction chemotherapy, because their 
clinical stages had been evaluated as 1A to 2A. Two fusion-positive adenocarcinomas were 
detected from pathological stage 1A tumors and three from stage 3A tumors. Four of the five 
patients with fusion-positive tumors were nonsmokers, and the only smoker had a 0.25 
pack/year smoking history, which was less than fusion-negative patients that smoked.  
Mutations of the EGFR and KRAS genes in NSCLCs 
Out of 313 samples, EGFR mutations were detected in 105 adenocarcinomas and in one 
squamous cell carcinoma. KRAS mutations were detected in 35 patients: 29 in 
adenocarcinomas, three in large cell carcinomas, two in squamous cell carcinomas, and 
one in pleomorphic carcinoma. ERBB2 mutations were detected in seven adenocarcinomas 
and in one squamous cell carcinoma (Table 3). All five fusion-positive adenocarcinomas had 
wild-type EGFR, KRAS, and ERBB2 genes (Table 2). Further, tumors with the EML4-ALK 
fusion had no p53 (exons 5-8) gene mutations (data not shown).  
Prognosis and overall survival of the EML4-ALK fusion-harboring patients 
Two patients with p-stage 1A adenocarcinoma received no adjuvant therapy and survived 
for over 66 months (patient 1) and 60 months (patient 2) without any recurrence or 
metastasis (Table 1). A patient with p-stage 3A adenocarcinoma (patient 3) underwent a 
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right upper lobectomy, followed by two cycles of combined adjuvant chemotherapy with a 
carboplatin plus paclitaxel regimen. A metastatic lesion appeared in the remaining middle 
lobe, and a right middle lobectomy was performed 73 months after the primary lung 
resection. Histopathological studies determined that the tumor in the resected right middle 
lobe and the anterior mediastinal lymph node (#3a) were a recurrent tumor and metastatic 
lymph node of the primary tumor. Additional RT-PCR assays revealed that the relapsed 
tumor cells in the right middle lobe harbored the same EML4-ALK fusion. Histopathological 
studies demonstrated that this second tumor had the same characteristics as the primary 
resected tumor. With 100 mg/day of S-1 (Tegafur/ Gimeracil/ Oteracil) medication, patient 3 
survived for over 99 months following the first pulmonary resection (26 months after the 
second resection). 
Two patients with p-stage 3A adenocarcinoma (patients 4 and 5) underwent a left upper 
lobectomy and a left lower lobectomy, respectively. Patient 4 underwent two cycles of 
adjuvant chemotherapy with the carboplatin plus paclitaxel regimen. Multiple brain 
metastases appeared 16 months after the pulmonary resection, and whole brain radiation 
therapy (30 Gy/ 10 fractures) was performed. Patient 4 died 28 months after the operation. 
Eight months after the lobectomy, chest CT studies revealed that patient 5 had a metastatic 
nodule in the right lower lung and metastatic lymph nodes in the left mediastinum. This 
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patient underwent two cycles of chemotherapy with the carboplatin plus paclitaxel regimen. 
Seventeen months after the resection, a metastatic lesion was found in the brain. Patient 5 
then underwent gamma knife radio-surgery with vinorelbine. Metastatic lesions in the 
mediastinum and liver grew, and patient 5 died 53 months after the pulmonary resection. 
Histopathological analysis of EML4-ALK fusion-harboring tumors 
One of the five fusion-harboring adenocarcinomas was an acinar adenocarcinoma, and the 
other four were classified as mixed subtype adenocarcinomas: two of the acinar 
predominant subtype and two of the papillary predominant subtype. The four 
adenocarcinomas of mixed subtype were evaluated as poorly differentiated (Grade 3), and 




Using RT-PCR analysis, we detected five EML4-ALK fusion genes from among 313 NSCLC 
specimens (1.6%). The frequency rates for EML4-ALK fusions in NSCLCs have been 
reported in several studies,23, 27, 31-35 and our results are comparable with the previously 
published data. In our study, samples were collected entirely from a Japanese population; 
the frequency of EML4-ALK fusions was similar to that of U.S. plus Korean,27 European,36 or 
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Chinese37 populations. This finding suggests that there is no significant difference in the 
frequency of EML4-ALK fusion genes between countries. 
The prognosis and the clinical course after primary tumor resection of our patients with 
EML4-ALK fusion-harboring NSCLC seemed to be relatively favorable. Both of the patients 
with pathological grade 1A adenocarcinomas survived for over 60 months without any 
recurrence or metastasis. One with a pathological grade 3A adenocarcinoma (Patient 2) 
survived for over 99 months, with pulmonary metastasis occurring 73 months after the 
primary lung resection. This case showed that an EML4-ALK fusion positive tumor could 
relapse after a long interval (>60 months), but adequate local and systemic control could 
provide an excellent survival benefit. One patient with a pathological grade 3A 
adenocarcinoma had brain metastasis 8 months after the operation, yet still survived 53 
months. Inamura and colleagues (2007) reported six patients with pathological grade 1A 
adenocarcinomas and two patients with grade 3A adenocarcinomas who survived over 59.0 
± 8.8 months and 39 ± 6.9 months, respectively.35 Because there are not enough clinical 
data dealing with fusion-harboring patients thus far, it is difficult to appreciate the prognosis 
of EML4-ALK fusion-positive patients statistically. However, considering the Inamura and 
colleagues (2007) report and our data, genetic alterations producing EML4-ALK fusions may 
not be an unfavorable prognostic factor for adenocarcinoma patients.  
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We investigated the incidence of EML4-ALK in this relatively large-scale screen and 
analyzed its characteristics according to the age, sex, and smoking habits of the patients, as 
well as the histology, differentiation, and p-stage of the tumors. Of the five EML4-ALK 
fusion-harboring adenocarcinoma patients, four were female. The fusion-positive patients 
were mostly non-smokers; only one patient had a smoking history of a 0.25 pack/year. It 
should be noted that the pack/year number of fusion-positive patients was smaller than that 
of fusion-negative patients (Table 2; 0.05 ± 0.01 vs. 29.6 ± 36.6, p<0.001).  
All five fusions were detected only in adenocarcinomas (Table 3). These findings may 
indicate that the EML4-ALK fusion gene is related to the oncogenes that have been mutated 
in some nonsmokers’ lung adenocarcinomas. This tendency is compatible with several 
previously reported results.25, 35, 37 This finding also suggests the importance of patient 
selection for gene-targeted therapy using ALK kinase inhibitors, because the efficiency of 
tyrosine kinase inhibition is strongly related to typical clinicopathologic backgrounds, as is 
recognized for the use of gefitinib and erlotinib. Our data and that of previous investigators 
indicate the specific clinicopathologic features of candidates for ALK tyrosine kinase inhibitor 
therapy. 
As shown in this and other studies,10-12, 24, 28, 38-45 about half of Japanese lung 
adenocarcinomas harbor a mutation in EGFR, 10-15% in KRAS, and 4-6% in ERBB2. Our 
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genetic analysis of the EGFR, KRAS and ERBB2 genes demonstrated that the EML4-ALK 
fusion gene is mutually exclusive with mutations in these genes. Therefore, two-thirds of 
lung adenocarcinomas are classified based on the genetic alterations of their tyrosine 
kinase, which indicates that most adenocarcinomas are candidates for gene-targeted 
therapy, especially therapy involving tyrosine kinase inhibitors. 
Usually, gefitinib or erlotinib therapy has been applied to control locally advanced or 
metastatic adenocarcinomas after several regimens of chemotherapy. Up to the present, 
most of adenocarcinoma treated with these tyrosine kinase inhibitors have not been 
confirmed their EGFR gene status because screening for mutations in the EGFR has not 
been practical due to financial problems and/or technical inconvenience. According to the 
findings from many researchers and our study, good responders to gefitinib or erlotinib can 
be estimated to harbor mutations in the EGFR gene and not the EML4-ALK fusions. At 
present, as gefitinib or erlotinib are usually applied for certain adenocarcinoma patient 
groups with specific clinical characteristics (e.g., Asian, female, and non-smokers), their 
efficiency are getting more favorable. Nevertheless, some non-responders would be left and 
a certain number of EML4-ALK fusion-harboring adenocarcinomas would hide behind them. 
Therefore, we considered that it would be very beneficial to demonstrate RT-PCR assays for 
detection of the EML4-ALK fusions in tumors of the non-responders to such conventional 
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EGFR kinase inhibitors. We believe this easy and economical screening method and the 
future ALK kinase targeted therapy would be very significant for treatment of the EML4-ALK 
fusion-harboring adenocarcinomas. 
Nine EML4-ALK variants have been previously identified by other investigators: 1, 2, 3a, 3b, 
4, 5a, 5b, 6, and 7. Variants 1, 2, 3a, and 5a consist of a simple fusion between an exon of 
EML4 (exons 13, 20, 6, and 2, respectively) and exon 20 of the ALK gene. Variant 3b 
involves a 33-bp insertion between exon 6 of EML4 and exon 20 of ALK, and variant 5b 
involves a 117-bp insertion between exon 2 of EML4 and exon 20 of ALK. In variant 4, the 
EML4 exon 14 is fused via an 11-bp insertion to the 50th nucleotide of ALK exon 20. EML4 
exon 13 is fused 69-bp upstream of ALK exon 20 in variant 6, and EML4 exon 14 is fused to 
nucleotide 13 of ALK exon 20 in variant 7.46 Here, we have identified two novel EML4-ALK 
fusion variants. In the tumor of patient 4, EML4 exon 20 was fused via an 18-bp sequence to 
ALK exon 20. The inserted sequence of this variant comprises the last 18-bp of ALK intron 
19. Thus, this fusion can be classified as a subtype of variant 2. Compared with variant 2, 
the fusion sequence of patient 5 had a 275-bp deletion of full length of EML4 exon 18 
(89-bp), exon 19 (98-bp), and exon 20 (88-bp), and a 68-bp insertion. Therefore, the fusion 
from patient 5 had a 207-bp smaller sequence than variant 2, which does not provide frame 
shift. This type of fusion was unique, because it contained mixed sequences from ALK 
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introns between the EML4 and ALK exons. The characteristic phenomenon of this variant 
was that the inserted sequences were composed of three ALK intron sequences. We could 
not find ALK intron components in the other types of variants containing inserted sequence 
between EML4 and ALK. Above all, the most peculiar features of the fusion gene from 
patient 5 were eleven sequences identical to the first 14-bp, and another 42 of 15-bp, ALK 
intron sequences and their reversed sequences. Reversed sequences were correlated with 
the existence of identical sequences on anti-sense DNA, scattered around the ALK introns. 
There is no confirmed evidence, but this uncommon event of quite a number of duplicated 
sequences may induce altered EML4-ALK fusion conformation. Unfortunately, due to the 
small number of EML4-ALK fusion samples, the influence of fusion variations on 
clinicopathologic features remains unknown.    
According to the WHO classification of lung tumors (2004), adenocarcinomas can be 
classified as acinar and papillary adenocarcinomas, bronchioloalveolar carcinoma, solid 
adenocarcinoma with mucin production, mixed subtype adenocarcinomas, and their variants. 
In our study, one fusion-positive sample was an acinar carcinoma, and four were 
adenocarcinomas of mixed subtype (two of the acinar predominant type and two of the 
papillary predominant type). Inamura and colleagues (2009) reported the detection of five 
fusion-positive adenocarcinomas out of 206 papillary predominant subtypes and six out of 
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34 acinar predominant subtypes,35 showing a significantly higher tendency for fusions in 
acinar-predominant subtype adenocarcinomas. Considering these findings, EML4-ALK 
fusion-harboring adenocarcinomas are likely to be related to acinar components. 
In conclusion, we determined that EML4-ALK fusion-harboring lung cancers were only 
present in adenocarcinomas and in patients with little or no smoking history in our test group. 
In addition, we concluded that the EML4-ALK fusions were mutually exclusive with 
mutations in the EGFR, KRAS, and ERBB2 genes. These observations provide additional 
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RT-PCR studies using the EML4 (exon 2)-ALK primer set. The λ DNA-HindIII Digest 
(BioLabs) and the φX174 HaeIII digest (Takara Bio) were used as the DNA ladder markers. 
In each patient (1-5), a single band was amplified, and its size was subsequently 
determined: 1357-2027 bp band in patient 1, 603-872 bp band in patient 2, 603-872 bp band 
in patient 3, 2027-2322 bp band in patient 4, and 2027-2322 bp band in patient 5. 
Figure 1B   
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RT-PCR studies using the EML4 (exon13)-ALK primer set. The same DNA ladder markers 
as above were used. A single band was amplified in three of the five patients, and the sizes 
were subsequently determined: a <281 bp band in patient 1, 872-1078 bp band in patient 4, 
and 603-872bp band in patient 5. No RT-PCR products were obtained in patients 2 and 3. 
Figure 2A 
Schema showing two novel EML4-ALK fusion variants and variant 2. In patient 4, exon 20 of 
EML4 is fused via an 18-bp sequence to exon 20 of ALK. This fusion could be classified as a 
subtype of variant 2. In patient 5, exon 17 of EML4 is fused via a 68-bp insertion to exon 20 
of ALK. Compared with variant 2, this fusion type had a full length deletion EML4 exon 18-20 
(275-bp) and a 68-bp insertion. This results in a 207-bp shorter fusion sequence than variant 
2, which provided no frame shift.  
Figure 2B 
Schema showing the fusion pattern of patient 4 with precise sequence information. The 
inserted sequence was identical to the last part of ALK intron 19, which indicates that the 
break point of ALK is 18-bp upstream of that in variant 2.  
Figure 2C 
Schema showing the location of identical sequences composing inserted sequences. Three 
parts of the inserted sequence are named A, B, and C. Sequences marked as “A” and a left 
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arrow indicate the sequence 5’-AGTCTTGCTCTGTC-3’, and those marked as “A” and a 
right arrow indicate the reversed sequence 5’-GACAGAGCAAGACT-3’. Sequences 
marked as “B” with a left arrow indicate the sequence 5’-TCCCAGGCTGGAGTGCAGT-3’, 
and those marked by “B” with a right arrow indicate the reversed sequence. Sequence 
marked as “C” with a left arrow indicates the 35-bp sequence 
5’-GGCAATTTACACATTTCAATTCATTCGATCCTCAG-3’.  
Figure 3   
Histopathological studies of EML4-ALK fusion-harboring tumors. All of the carcinomas were 
adenocarcinomas. One was an acinar adenocarcinoma (patient 2), and the other four were 
classified as adenocarcinomas of mixed subtypes. In patients 3 and 4, acinar characteristics 
were evaluated to be predominant. The acinar adenocarcinoma in patient 2 was classified 
as moderately differentiated, and the others were all classified as poorly differentiated 









Table 1. Clinical Features and Details of EML4-ALK Fusion Gene Positive Patients




























1 77 F Ad with mixed subtypes Papillary Poor 1A LUL V1 0 66M alive 66M none - - -
2 72 F Acinar Ad Acinar Mod 1A LUL V3b 0 60M alive 60M none - - -
3 53 M Ad with mixed subtypes Acinar Poor 3A RUL V3a 0.25 99M alive 73M lung - - -
4 75 F Ad with mixed subtypes Acinar Poor 3A LUL novel type 0 28M dead 16M brain - - -
5 73 F Ad with mixed subtypes Papillary Poor 3A LLL novel type 0 53M dead 8M brain - - -
Pt, patient; Ad, adenocarcinoma; diff , differentiation; Mod, moderately differentiated; p-stage, pathological stage; LUL, left upper lobe; RUL, right































Total (+) (n=5) (-) (n=206) P
70.0 ± 9.7 65.2 ± 10.1 0.29
Sex
Male 111 1 110 0.31
Female 100 4 96
Smoking
Never 92 4 88 0.58
Smoker 119 1 118
0.05 ± 0.11 29.6 ± 36.6 p<0.001
Differentiation
Well 87 0 86 p<0.01†
Moderate 91 1 87
Poor 33 4 33
p-Stage
I 141 2 139 0.16‡
II 20 0 20
III 42 3 39
IV 8 0 8
EGFR
Wild type 106 5 101 0.072
Mutated 105 0 105
KRAS
Wild type 182 5 177 0.81
Mutated 29 0 29
ERBB2
Wild type 204 5 199 0.40
Mutated 7 0 7




Pack-year (mean ± SD)
† well plus moderately differentiated adenocarcinomas vs. poorly differentiated adenocarcinomas;











carcinoma (n=75) Others (n=27)
65.3 69.6 64.0
Sex Male 202 111 66 25
Female 111 100 9 2
Smoking
Never 97 92 3 2
Smoker (ex- / current) 216 119 72 25
       Pack-year (mean ± SD) 28.9 ± 46.6 60.1 ± 37.1 54.2 ± 33.8  
Differentiation
Well 91 87 3 0
Moderate 143 91 52 4
Poor 80 33 20 21
p-Stage
I 197 141 43 13
II 37 20 13 4
III 70 42 19 9
IV 9 8 0 1
EGFR
Wild type 207 106 74 27
Mutated 106 105 1 0
KRAS
Wild type 278 182 73 23
Mutated 35 29 2 4
ERBB2
Wild type 305 204 74 27
Mutated 8 7 1 0
negative 308 206 75 27
positive 5 5 0 0
















RT-PCR studies using the EML4 (exon 2)-ALK primer set. The λ DNA-HindIII Digest 
(BioLabs) and the φX174 HaeIII digest (Takara Bio) were used as the DNA ladder markers. 
In each patient (1-5), a single band was amplified, and its size was subsequently 
determined: 1357-2027 bp band in patient 1, 603-872 bp band in patient 2, 603-872 bp band 












RT-PCR studies using the EML4 (exon13)-ALK primer set. The same DNA ladder markers 
as above were used. A single band was amplified in three of the five patients, and the sizes 
were subsequently determined: a <281 bp band in patient 1, 872-1078 bp band in patient 4, 











Schema showing two novel EML4-ALK fusion variants and variant 2. In patient 4, exon 20 of 
EML4 is fused via an 18-bp sequence to exon 20 of ALK. This fusion could be classified as a 
subtype of variant 2. In patient 5, exon 17 of EML4 is fused via a 68-bp insertion to exon 20 
of ALK. Compared with variant 2, this fusion type had a full length deletion EML4 exon 18-20 
(275-bp) and a 68-bp insertion. This results in a 207-bp shorter fusion sequence than variant 





Schema showing the fusion pattern of patient 4 with precise sequence information. The 
inserted sequence was identical to the last part of ALK intron 19, which indicates that the 











Schema showing the location of identical sequences composing inserted sequences. Three 
parts of the inserted sequence are named A, B, and C. Sequences marked as “A” and a left 
arrow indicate the sequence 5’-AGTCTTGCTCTGTC-3’, and those marked as “A” and a 
right arrow indicate the reversed sequence 5’-GACAGAGCAAGACT-3’. Sequences marked 
as “B” with a left arrow indicate the sequence 5’-TCCCAGGCTGGAGTGCAGT-3’, and 
those marked by “B” with a right arrow indicate the reversed sequence. Sequence marked 







Histopathological studies of EML4-ALK fusion-harboring tumors. All of the carcinomas were 
adenocarcinomas. One was an acinar adenocarcinoma (patient 2), and the other four were 
classified as adenocarcinomas of mixed subtypes. In patients 3 and 4, acinar characteristics 
were evaluated to be predominant. The acinar adenocarcinoma in patient 2 was classified 
as moderately differentiated, and the others were all classified as poorly differentiated 
(grade 3) types. 
 
